Skip to main content
Journal cover image

Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor.

Publication ,  Journal Article
Long, Q; He, M; Tang, X; Allotey, P; Tang, S
Published in: Diabetic medicine : a journal of the British Diabetic Association
January 2017

This study aims to investigate the medical expenditure of people with Type 2 diabetes mellitus in Chongqing, China; to explore factors that contribute to the expenditure; and to examine the financial burden placed on households, particularly poor households.A cross sectional survey was conducted with a sample of people diagnosed with Type 2 diabetes mellitus in 2014. Of the 664 people eligible, 76% were interviewed. Descriptive statistics and log-linear regression were used to examine respondents' age, sex and level education, location of residence, income and type of health insurance associated with out-of-pocket expenditure on accessing diabetes mellitus care.In a year, average out-of-pocket expenditure on the purchase of drugs from pharmacies and having outpatient care were US $333 and US $310, respectively. The average out-of-pocket expenditure on accessing inpatient care was 3.7 times (US $1159) that of accessing outpatient care. After adjusting for age and sex, out-of-pocket expenditure on diabetes care was significantly higher for people covered by the Urban Employee Basic Medical Insurance programme and those enrolled in the identified priority diseases reimbursement programme, which provided higher reimbursement rates for outpatient and (or) inpatient care. Out-of-pocket expenditures on the purchase of drugs from pharmacies, having outpatient and inpatient care, respectively, were 9.8%, 16.2% and 62.6% of annual household income in low-income group.Even with health insurance coverage, poor people with Type 2 diabetes mellitus suffered from significant financial hardship. This has significant implications for models of care and healthcare financing in China with the growing burden of diabetes.

Duke Scholars

Published In

Diabetic medicine : a journal of the British Diabetic Association

DOI

EISSN

1464-5491

ISSN

0742-3071

Publication Date

January 2017

Volume

34

Issue

1

Start / End Page

120 / 126

Related Subject Headings

  • Prescription Fees
  • Poverty
  • Middle Aged
  • Male
  • Insurance, Health, Reimbursement
  • Hypoglycemic Agents
  • Humans
  • Hospital Charges
  • Healthcare Disparities
  • Health Transition
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Long, Q., He, M., Tang, X., Allotey, P., & Tang, S. (2017). Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor. Diabetic Medicine : A Journal of the British Diabetic Association, 34(1), 120–126. https://doi.org/10.1111/dme.13193
Long, Q., M. He, X. Tang, P. Allotey, and S. Tang. “Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor.Diabetic Medicine : A Journal of the British Diabetic Association 34, no. 1 (January 2017): 120–26. https://doi.org/10.1111/dme.13193.
Long Q, He M, Tang X, Allotey P, Tang S. Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor. Diabetic medicine : a journal of the British Diabetic Association. 2017 Jan;34(1):120–6.
Long, Q., et al. “Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor.Diabetic Medicine : A Journal of the British Diabetic Association, vol. 34, no. 1, Jan. 2017, pp. 120–26. Epmc, doi:10.1111/dme.13193.
Long Q, He M, Tang X, Allotey P, Tang S. Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor. Diabetic medicine : a journal of the British Diabetic Association. 2017 Jan;34(1):120–126.
Journal cover image

Published In

Diabetic medicine : a journal of the British Diabetic Association

DOI

EISSN

1464-5491

ISSN

0742-3071

Publication Date

January 2017

Volume

34

Issue

1

Start / End Page

120 / 126

Related Subject Headings

  • Prescription Fees
  • Poverty
  • Middle Aged
  • Male
  • Insurance, Health, Reimbursement
  • Hypoglycemic Agents
  • Humans
  • Hospital Charges
  • Healthcare Disparities
  • Health Transition